Fig. 2

Chronic glymphatic inhibition exacerbates tau propagation in a mouse model. A Representative examples of AT8 immunoreactivity in the hippocampus of treated mice groups. B Quantification of AT8 immunopositive staining (% area) in the hippocampus indicates a trend towards increased tau pathology in ^P301SBE injected transgenic mice, but no apparent difference between TGN-020 treated and vehicle treated animals. When subdivided into hemispheres however (C), TGN-020 treated ^P301SBE infused mice exhibited a significant increase in immunoreactive intensity compared to vehicle treated animals. Contralateral tau signal intensity was also significantly greater in TGN-020 treated mice compared to vehicle treatment, which was made more clear when calculating the interhemispheric intensity ratio in tau injected mice (D). A similar trend of increased tau load was observed in the cortex (E), i.e. the other region of the brain to receive tau inoculation. However no differences in tau signal intensity were seen here between treatment groups (F) or between hemispheres of tau injected mice (G). ▲=females, ■=males, *=p < 0.05, **=p < 0.01,, ***=p < 0.001, n = 5–8 per group